Constructing the cGAMP‐Aluminum Nanoparticles as a Vaccine Adjuvant‐Delivery System (VADS) for Developing the Efficient Pulmonary COVID‐19 Subunit Vaccines
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202401650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Ning Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Food and Bioengineering, Hefei University of Technology, 420 Jade Road, Hefei, Anhui Province, 230601, China. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Adjuvants, Immunologic, SARS-CoV-2. Die Arbeit nennt 115 Literaturangaben. Gefördert von: Anhui Provincial Natural Science Foundation, Anhui Medical University, Natural Science Foundation of Anhui Province.
Abstract (Originalsprache)
The cGAMP‐aluminum nanoparticles (CAN) are engineered as a vaccine adjuvant‐delivery system to carry mixed RBD (receptor‐binding domain) of the original severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its new variant for developing bivalent pulmonary coronavirus disease 2019 (COVID‐19) vaccines (biRBD‐CAN). High phosphophilicity/adsorptivity made intrapulmonary CAN instantly form the pulmonary ingredient‐coated CAN (piCAN) to possess biomimetic features enhancing biocompatibility. In vitro biRBD‐CAN sparked APCs (antigen‐presenting cells) to mature and make extra reactive oxygen species, engendered lysosome escape effects and enhanced proteasome activities. Through activating the intracellular stimulator of interferon genes (STING) and nucleotide‐binding domain and leucine‐rich repeat and pyrin domain containing proteins 3 (NALP3) inflammasome pathways to exert synergy between cGAMP and AN, biRBD‐CAN stimulated APCs to secret cytokines favoring mixed Th1/Th2 immunoresponses. Mice bearing twice intrapulmonary biRBD‐CAN produced high levels of mucosal antibodies, the long‐lasting systemic antibodies, and potent cytotoxic T lymphocytes which efficiently erased cells displaying cognate epitopes. Notably, biRBD‐CAN existed in mouse lungs and different lymph nodes for at least 48 h, unveiling their sustained immunostimulatory activity as the main mechanism underlying the long‐lasting immunity and memory. Hamsters bearing twice intrapulmonary biRBD‐CAN developed high resistance to pseudoviral challenges performed using different recombinant strains including the ones with distinct SARS‐CoV‐2‐spike mutations. Thus, biRBD‐CAN as a broad‐spectrum pulmonary COVID‐19 vaccine candidate may provide a tool for controlling the emerging SARS‐CoV‐2 variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Food and Bioengineering, Hefei University of Technology, 420 Jade Road, Hefei, Anhui Province, 230601, China.
- School of Pharmacy, Anhui Medical University, 81 Plum Hill Road, Hefei, Anhui Province, 230032, China.
- Department of Pharmacy, The Second People's Hospital of Lianyungang, 41 Hailian East Road, Lianyungang, Jiangsu Province, 222006, China.
ORCID-Profile: Ting Wang
Förderung
- Anhui Provincial Natural Science Foundation
- Anhui Medical University
- Natural Science Foundation of Anhui Province
Zitieren
APA
Wang, N., Wang, C., Wei, C., Chen, M., Gao, Y., Zhang, Y., & Wang, T. (2024). Constructing the cGAMP‐Aluminum Nanoparticles as a Vaccine Adjuvant‐Delivery System (VADS) for Developing the Efficient Pulmonary COVID‐19 Subunit Vaccines. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401650
Vancouver
Wang N, Wang C, Wei C, Chen M, Gao Y, Zhang Y, et al. Constructing the cGAMP‐Aluminum Nanoparticles as a Vaccine Adjuvant‐Delivery System (VADS) for Developing the Efficient Pulmonary COVID‐19 Subunit Vaccines. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202401650
BibTeX
@article{Wang2024,
author = {Wang, Ning and Wang, Can and Wei, Chunliu and Chen, Minnan and Gao, Yuhao and Zhang, Yuxi and Wang, Ting},
title = {Constructing the cGAMP‐Aluminum Nanoparticles as a Vaccine Adjuvant‐Delivery System (VADS) for Developing the Efficient Pulmonary COVID‐19 Subunit Vaccines},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202401650}
}
EUVIMED